Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer

Mario A. Eisenberger(Johns Hopkins University), Bruce A. Lowe(Oregon Health & Science University)
New England Journal of Medicine
October 8, 1998
10.1056/nejm199810083391504
Cited by 868

Related Papers

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
|European Urology|2018|110
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy
|Cancer|2012|107
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
|European Urology|2021|65